• Rui Plácido, Nuno Cortez-Dias, Robalo MartinsSusanaSCardiology Department, Santa Maria Hospital, Lisbon Academic Medical Centre, CCUL, Lisbon, Portugal., Gomes AlmeidaAnaACardiology Department, Santa Maria Hospital, Lisbon Academic Medical Centre, CCUL, Lisbon, Portugal., Carina Calisto, Susana Gonçalves, Malha Sadoune, Nunes DiogoAntónioACardiology Department, Santa Maria Hospital, Lisbon Academic Medical Centre, CCUL, Lisbon, Portugal., Alexandre Mebazaa, and Fausto José Pinto.
• Cardiology Department, Santa Maria Hospital, Lisbon Academic Medical Centre, CCUL, Lisbon, Portugal. Electronic address: placidorui@gmail.com.
• Rev Port Cardiol. 2017 Feb 1; 36 (2): 111-125.

IntroductionPulmonary hypertension (PH) covers a group of conditions characterized by an increase in pulmonary vascular resistance leading to right ventricular failure. Risk stratification is crucial for adequate prognostic and therapeutic assessment. However, the accuracy of conventional parameters is limited, especially biomarkers.ObjectivesTo determine the prognostic value of new biomarkers and their combination in a multi-biomarker approach to predict outcome in patients with PH.MethodsIn this prospective cohort study, PH patients underwent clinical, echocardiographic and laboratory assessment, including quantification of serum N-terminal pro-brain natriuretic peptide (NT-proBNP) and of the following new biomarkers: mid-regional pro-adrenomedullin (MR-proADM), copeptin, endothelin-1, mid-regional pro-atrial natriuretic peptide (MR-proANP) and soluble ST2 (sST2), the interleukin-33 receptor. The accuracy of the different parameters for predicting all-cause mortality and death or hospitalization of cardiac causes was determined. The prognostic value of a multi-biomarker score based on the tertile distribution of serum NT-proBNP, MR-proANP, renin and sST2 was compared to conventional markers.ResultsForty-three patients (72.1% female, age 59±15 years) were included, most of whom (65.1%) had group 1 PH. During a median follow-up of 34 months, 26% of the patients died and 35% were hospitalized for cardiac causes. Atrial and ventricular dimensions and right ventricular fractional area change were prognostic predictors. Log NT-proBNP (HR: 31.14; 95% CI: 3.12-310.7; p=0.003) and renin (HR: 1.02; 95% CI: 1.005-1.038; p=0.009) were independent predictors of mortality. MR-proANP (HR: 1.008; 95% CI 1.004-1.011; p<0.001) and sST2 (HR: 1.005; 95% CI 1.001-1.009; p=0.04) were predictors of death or hospitalization. The prognostic value of the multi-biomarker score was higher than any of the conventional parameters, and enabled identification of risk groups (the high-risk group had three-year mortality of 77.8%).ConclusionA multi-biomarker approach was superior for risk stratification to any single marker. A score that incorporates NT-proBNP, MR-proANP, renin and sST2 accurately identifies patients at low, intermediate and high risk.Copyright © 2016 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. All rights reserved.

20 keywords...

hide…